WO2008109712A3 - Systèmes de distribution de nanoparticules pour des peptides d'intégration de la membrane - Google Patents

Systèmes de distribution de nanoparticules pour des peptides d'intégration de la membrane Download PDF

Info

Publication number
WO2008109712A3
WO2008109712A3 PCT/US2008/055969 US2008055969W WO2008109712A3 WO 2008109712 A3 WO2008109712 A3 WO 2008109712A3 US 2008055969 W US2008055969 W US 2008055969W WO 2008109712 A3 WO2008109712 A3 WO 2008109712A3
Authority
WO
WIPO (PCT)
Prior art keywords
membrane
delivery systems
nanoparticle delivery
integrating peptides
peptides
Prior art date
Application number
PCT/US2008/055969
Other languages
English (en)
Other versions
WO2008109712A2 (fr
Inventor
Paul Schlesinger
Neelesh Soman
Gregory Lanza
Samuel A Wickline
Original Assignee
Univ Washington
Paul Schlesinger
Neelesh Soman
Gregory Lanza
Samuel A Wickline
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Paul Schlesinger, Neelesh Soman, Gregory Lanza, Samuel A Wickline filed Critical Univ Washington
Priority to CA2680206A priority Critical patent/CA2680206C/fr
Priority to AU2008222822A priority patent/AU2008222822A1/en
Priority to JP2009552872A priority patent/JP5249248B2/ja
Priority to EP08731481.1A priority patent/EP2120876B1/fr
Publication of WO2008109712A2 publication Critical patent/WO2008109712A2/fr
Publication of WO2008109712A3 publication Critical patent/WO2008109712A3/fr
Priority to HK10104967.9A priority patent/HK1139053A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'invention concerne des compositions comprenant des émulsions de nanoparticules pour la distribution de peptides d'intégration de la membrane. Les nanoparticules comprennent un noyau hydrophobe liquide revêtu d'une couche de lipide/agent tensioactif contenant les peptides d'intégration de la membrane. Des procédés d'utilisation de ces compositions sont également décrits.
PCT/US2008/055969 2007-03-05 2008-03-05 Systèmes de distribution de nanoparticules pour des peptides d'intégration de la membrane WO2008109712A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA2680206A CA2680206C (fr) 2007-03-05 2008-03-05 Systemes de distribution de nanoparticules pour des peptides d'integration de la membrane
AU2008222822A AU2008222822A1 (en) 2007-03-05 2008-03-05 Nanoparticle delivery systems for membrane-integrating peptides
JP2009552872A JP5249248B2 (ja) 2007-03-05 2008-03-05 膜組み込みペプチドのためのナノ粒子輸送システム
EP08731481.1A EP2120876B1 (fr) 2007-03-05 2008-03-05 Systèmes de libération de nanoparticules pour des peptides qui sont intégrés dans la membrane
HK10104967.9A HK1139053A1 (en) 2007-03-05 2010-05-20 Nanoparticle delivery systems for membrane-integrating peptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90522707P 2007-03-05 2007-03-05
US60/905,227 2007-03-05
US99165407P 2007-11-30 2007-11-30
US60/991,654 2007-11-30

Publications (2)

Publication Number Publication Date
WO2008109712A2 WO2008109712A2 (fr) 2008-09-12
WO2008109712A3 true WO2008109712A3 (fr) 2008-12-11

Family

ID=39739102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055969 WO2008109712A2 (fr) 2007-03-05 2008-03-05 Systèmes de distribution de nanoparticules pour des peptides d'intégration de la membrane

Country Status (7)

Country Link
US (2) US7943168B2 (fr)
EP (1) EP2120876B1 (fr)
JP (1) JP5249248B2 (fr)
AU (1) AU2008222822A1 (fr)
CA (1) CA2680206C (fr)
HK (1) HK1139053A1 (fr)
WO (1) WO2008109712A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2209420A4 (fr) 2007-10-09 2014-01-22 Univ St Louis Particules d'imagerie
US9468607B2 (en) 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
WO2009151788A2 (fr) * 2008-04-22 2009-12-17 The Washington University Peptide d’ancrage universel pour des nanoparticules
CN106362171A (zh) * 2009-02-13 2017-02-01 华盛顿大学 用于磁共振成像的钆表现脂质纳米颗粒
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
US9764043B2 (en) 2009-12-17 2017-09-19 Washington University Antithrombotic nanoparticle
AU2011239414A1 (en) 2010-04-15 2012-11-08 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
EP2600901B1 (fr) 2010-08-06 2019-03-27 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
ES2737960T3 (es) 2010-10-01 2020-01-17 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos
US20120100186A1 (en) * 2010-10-20 2012-04-26 Washington University Nanoparticulate-based contraceptive/anti-hiv composition and methods
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3682905B1 (fr) 2011-10-03 2021-12-01 ModernaTX, Inc. Nucléosides, nucléotides et acides nucléiques modifiés et leurs utilisations
WO2013082304A1 (fr) * 2011-11-29 2013-06-06 The Regents Of The University Of California Reconfiguration de circuit génique à médiation par une nanoantenne photonique
EP2791160B1 (fr) 2011-12-16 2022-03-02 ModernaTX, Inc. Compositions de mrna modifiés
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP4074834A1 (fr) 2012-11-26 2022-10-19 ModernaTX, Inc. Arn à terminaison modifiée
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
CA2926218A1 (fr) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides codant pour un recepteur de lipoproteines de faible densite
BR112016024644A2 (pt) 2014-04-23 2017-10-10 Modernatx Inc vacinas de ácido nucleico
US20160296628A1 (en) * 2015-01-23 2016-10-13 Washington University Nanoparticle delivery systems for cytolytic peptide prodrugs
WO2017031232A1 (fr) 2015-08-17 2017-02-23 Modernatx, Inc. Procédés de préparation de particules et compositions associées
PT3350157T (pt) 2015-09-17 2022-03-18 Modernatx Inc Compostos e composições para administração intracelular de agentes terapêuticos
EP3964200A1 (fr) 2015-12-10 2022-03-09 ModernaTX, Inc. Compositions et procédés permettant d'administrer des agents thérapeutiques
AU2016377681B2 (en) 2015-12-22 2021-05-13 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
HRP20220525T1 (hr) 2015-12-23 2022-05-27 Modernatx, Inc. Postupci uporabe polinukleotida koji kodiraju ligand ox40
WO2017120612A1 (fr) 2016-01-10 2017-07-13 Modernatx, Inc. Arnm thérapeutiques codant pour des anticorps anti-ctla-4
WO2018089540A1 (fr) 2016-11-08 2018-05-17 Modernatx, Inc. Formulations stabilisées de nanoparticules lipidiques
US11969506B2 (en) 2017-03-15 2024-04-30 Modernatx, Inc. Lipid nanoparticle formulation
ES2911186T3 (es) 2017-03-15 2022-05-18 Modernatx Inc Formas cristalinas de aminolípidos
PL3596041T3 (pl) 2017-03-15 2023-03-06 Modernatx, Inc. Związek i kompozycje do dokomórkowego dostarczania środków terapeutycznych
WO2018213731A1 (fr) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucléotides codant pour des polypeptides d'interleukine-12 (il12) ancrés et leurs utilisations
AR120080A1 (es) 2019-09-19 2022-02-02 Modernatx Inc Compuestos lipídicos de cola ramificada y composiciones para la administración intracelular de agentes terapéuticos
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US20050177541A1 (en) * 2004-02-04 2005-08-11 Zorch, Inc. Method and system for dynamically updating a process library

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5645996A (en) 1994-08-24 1997-07-08 Torrey Pines Institute For Molecular Studies Melittin-related polypeptides, mixture sets and libraries thereof
JP3450318B2 (ja) 1994-11-21 2003-09-22 株式会社ワイ・ワイ・エル 熱電冷却型パワーリード
US6821506B2 (en) 1995-06-08 2004-11-23 Barnes-Jewish Hospital Site specific binding system, imaging compositions and methods
US6248353B1 (en) 1999-12-10 2001-06-19 Dade Behring Inc. Reconstitution of purified membrane proteins into preformed liposomes
US6780416B1 (en) * 2000-02-18 2004-08-24 Ecole Polytechnique Federale De Lausanne Bee venom polypeptides and methods of use thereof
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
WO2003062198A1 (fr) 2002-01-24 2003-07-31 Barnes Jewish Hospital Agents d'imagerie ciblant des integrines
EP1684724A4 (fr) 2003-11-19 2008-04-02 Barnes Jewish Hospital Apport ameliore d'un medicament
WO2007070827A2 (fr) * 2005-12-15 2007-06-21 Bristol-Myers Squibb Pharma Company Agents de contraste pour imagerie de perfusion myocardique
WO2009151788A2 (fr) * 2008-04-22 2009-12-17 The Washington University Peptide d’ancrage universel pour des nanoparticules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US20050177541A1 (en) * 2004-02-04 2005-08-11 Zorch, Inc. Method and system for dynamically updating a process library

Also Published As

Publication number Publication date
CA2680206A1 (fr) 2008-09-12
EP2120876A2 (fr) 2009-11-25
US7943168B2 (en) 2011-05-17
CA2680206C (fr) 2015-07-07
JP2010520304A (ja) 2010-06-10
HK1139053A1 (en) 2010-09-10
JP5249248B2 (ja) 2013-07-31
US20120128590A1 (en) 2012-05-24
EP2120876A4 (fr) 2012-08-15
WO2008109712A2 (fr) 2008-09-12
AU2008222822A2 (en) 2009-10-08
US8496945B2 (en) 2013-07-30
US20080274056A1 (en) 2008-11-06
AU2008222822A1 (en) 2008-09-12
EP2120876B1 (fr) 2015-03-04

Similar Documents

Publication Publication Date Title
WO2008109712A3 (fr) Systèmes de distribution de nanoparticules pour des peptides d'intégration de la membrane
WO2009149418A3 (fr) Nouvelles compositions pour l’administration in vivo d’agents arni
EP2054042B8 (fr) Procédés de préparation de composés biologiquement actifs sous forme de nanoparticules
WO2012162641A3 (fr) Système de revêtement de surface et procédé associé de préparation et d'utilisation
WO2012116246A3 (fr) Compositions pesticides et procédés associés
WO2013132491A3 (fr) Nanocomposites au spectre optique réglable
EP2607666A3 (fr) Radeau rigide
EP2057008A4 (fr) Couches hydrophobes en phases nanostructurées sur des substrats
EP2999751B8 (fr) Particules anti-corrosives
WO2009143450A3 (fr) Système de guidage et d’équilibrage actif pour ascenseur
WO2009123672A3 (fr) Activateur électrochimique
WO2010096733A3 (fr) Nanoparticules de silicium poreuses luminescentes, leurs procédés de production et d'utilisation
WO2009100803A3 (fr) Composition fluide pour affichage électrophorétique couleur
WO2013037764A3 (fr) Composant optoélectronique
ZA201004887B (en) Method for improving the hydrolysis stability of ionic liquids
WO2014059269A3 (fr) Compositions multicouches, dispositifs revêtus et leur utilisation
WO2011140330A3 (fr) Composition de rasage en aérosol comprenant un agent hydrophobe formant au moins une microgouttelette
EP2647039A4 (fr) Liquide de revêtement pour la formation d'une couche mince d'oxyde métallique, couche mince d'oxyde métallique, transistor à effet de champ et procédé de production du transistor à effet de champ
BR112012020180A2 (pt) "recipientes para fluidos com paredes hábeis de compósito"
GB0809629D0 (en) Hydrophobic coating composition
FR2910435B1 (fr) Compartiment de repos pour pilote d'aeronef.
FR2960216B1 (fr) Element d'aerodynamisme pour une nacelle d'aeronef
WO2008017957A3 (fr) Dispositifs contenant des émulsions lipidiques
WO2013013245A3 (fr) Nanosubstrats à distribution catalytique (cdns) pour la distribution très efficace de biomolécules
BRPI0811278A2 (pt) Sistema de aplicação possuindo um tanque de aerossol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731481

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009552872

Country of ref document: JP

Ref document number: 2680206

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008222822

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008731481

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008222822

Country of ref document: AU

Date of ref document: 20080305

Kind code of ref document: A